{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:17:36Z","timestamp":1767676656877,"version":"3.40.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.euroneuro.2022.03.001","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T18:40:35Z","timestamp":1647628835000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Precision psychiatry: The complexity of personalizing antipsychotic dosing"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2314","authenticated-orcid":false,"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.001_bib0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euroneuro.2021.10.863","article-title":"Stratified psychiatry: tomorrow\u2019s precision psychiatry?","volume":"2022","author":"Arns","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2022.03.001_bib0002","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/archpsyc.55.11.1048","article-title":"Very high cytochrome P4501A2 activity and nonresponse to clozapine","volume":"55","author":"Bender","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.001_bib0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.001_bib0004","first-page":"84","article-title":"High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers","volume":"49","author":"Chopra","year":"2020","journal-title":"Rev. Colomb. Psiquiatr. (Engl Ed)."},{"key":"10.1016\/j.euroneuro.2022.03.001_bib0005","first-page":"1","article-title":"Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase","author":"De Las Cuevas","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.001_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ps.55.2.125","article-title":"Psychopharmacology: atypical antipsychotic dosing: the effect of co-medication with anticonvulsants","volume":"55","author":"de Leon","year":"2004","journal-title":"Psychiatr. Serv."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.001_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/JCP.0b013e3182491383","article-title":"Evidence-based medicine versus personalized medicine: are they enemies?","volume":"32","author":"de Leon","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2022.03.001_bib0008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1017\/neu.2014.14","article-title":"Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry","volume":"26","author":"de Leon","year":"2014","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.euroneuro.2022.03.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.05.033","article-title":"Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics","volume":"168","author":"de Leon","year":"2020","journal-title":"Neuropharmacology."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.03.001_bib0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2022.03.001_bib0011","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2022.03.001_bib0012","first-page":"508","article-title":"CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: a systematic review","volume":"44","author":"Dorji","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"issue":"6","key":"10.1016\/j.euroneuro.2022.03.001_bib0013","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/JCP.0b013e3182a4ea8f","article-title":"A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism","volume":"33","author":"Riesselman","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2022.03.001_bib0014","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/pgs-2020-0015","article-title":"Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?","volume":"21","author":"Ruan","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.euroneuro.2022.03.001_bib0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/JCP.0000000000001125","article-title":"Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13","volume":"39","author":"Ruan","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"52","key":"10.1016\/j.euroneuro.2022.03.001_bib0016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euroneuro.2021.07.003","article-title":"Precision psychiatry: complex problems require complex solutions","volume":"2021","author":"Salagre","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.03.001_bib0017","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/JCP.0000000000001341","article-title":"European Whites may need lower minimum therapeutic clozapine doses than those customarily proposed","volume":"41","author":"Schoretsanitis","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2022.03.001_bib0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/17512433.2018.1478727","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.euroneuro.2022.03.001_bib0019","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.euroneuro.2022.03.001_bib0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.03.001_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/JCP.0000000000001507","article-title":"Effect of valproic acid on the metabolic spectrum of clozapine in patients with schizophrenia","volume":"42","author":"Smith","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.03.001_bib0022","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"12","key":"10.1016\/j.euroneuro.2022.03.001_bib0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/ph13120439","article-title":"Clinically relevant interactions between atypical antipsychotics and anti-infective agents","volume":"13","author":"Spina","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.03.001_bib0024","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/schbul\/sbab016","article-title":"Antipsychotic medications: enhancing use to improve outcomes","volume":"47","author":"Takeuchi","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.03.001_bib0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13318-021-00673-5","article-title":"The impact of smoking, sex, infection, and comedication administration on oral olanzapine: a population pharmacokinetic model in Chinese psychiatric patients","volume":"46","author":"Zang","year":"2021","journal-title":"Eur. J. Drug. Metab. Pharmacokinet."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T18:56:59Z","timestamp":1652381819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22001511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":25,"alternative-id":["S0924977X22001511"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.03.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision psychiatry: The complexity of personalizing antipsychotic dosing","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}